Correlation Between Brixia Score Imaging and Clinical Laboratory Results In Severe-Critical Covid-19 Patients Receiving Standard Therapy Compared To Tocilizumab
DOI:
https://doi.org/10.36408/mhjcm.v11i2.991Keywords:
COVID-19, Brixia score, tocilizumab, convalescent plasmaAbstract
Background. Coronavirus infection disease 19 (COVID-19) is a global health issue. Brixia score and inflammatory markers can assess COVID-19 severity. Severe-critical phase becomes the main concern of clinicians in the management of COVID-19 to reduce mortality. Standard therapy for moderate to severe COVID-19 is convalescent plasma which functions as an antiviral and immunomodulator, while tocilizumab is an IL-6 antagonist which underlies the occurrence of cytokine storms in severe-critical COVID-19.
Aims. To examine the correlation between the Brixia score and clinical laboratory results in patients with severe-critical degree of Covid-19 who received both standard therapy and tocilizumab
Method. A retrospective cohort study of Brixia score, with clinical laboratory results of D-dimer, fibrinogen, ferritin, and CRP (C-reactive protein) COVID-19 patients with severe-critical phase who were administered standard therapy and tocilizumab who were treated at RSUP DR Kariadi Semarang, then a correlation was carried out between the Brixia score and clinical laboratory results using a correlation test Spearman.
Results. The research data consisted of 72 subjects divided into groups that were adiminstered tocilizumab therapy (36 subjects) and standard therapy (36 subjects). There was a significant correlation between the Brixia score and the D-dimer result with p = 0.024 (p <0.05), correlation coefficient = 0.377 in the standard pre-therapy and post therapy. A p-value of less than 0.05 indicates no significant correlation between the Brixia score and clinical laboratory results before or after tocilizumab therapy.
Conclusion. There is a significant correlation between the Brixia score results and the D-dimer results in COVID-19 patients who are adiministered standard therapy, but not significant correlation in tocilizumab
Downloads
References
1. Covid Distribution Data. 2021. COVID-19 management and national recovery committee. Diakses accessed 3 March 2021 from : https://covid19.go.id/
2. Sussana D. When will the COVID-19 Pandemic in Indonesia End?. 2020. Jurnal Kesehatan Masyarakat Nasional (National Public Health Journal). 2020:1
3. Burhan E, Isbaniah F, Susanto AD, Aditama TY, All E. Pneumonia COVID- 19 Diagnonsis & Penatalaksanaan di Indonesia. Perhimpunan Dokter Paru Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2020.
4. Strunk JL, Temesgen H, Andersen H, Packalen P. Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review Authors: 2014;80(2):1–8.
5. Kong W, Agarwal PP. Chest Imaging Appearance of Covid-19 Infection. 2009. p. 1–30
6. Mathew SR. Comparison of tocilizumab and convalescent plasma therapy for COVID-19: A systematic review. J Bio Sci. 2020;6:579-584
7. Sofic, A., et al (2022). Brixia Chest X-ray Severity Scoring System is in Relation with C-reactive Protein and D-dimer Values in Patients with COVID-19. Materia socio-medica, 34(2), 95–99. https://doi.org/10.5455/msm.2022.34.95-99
8. Perrone, F., TOCIVID-19 investigators, Italy (2020). Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of translational medicine, 18(1), 405. https://doi.org/10.1186/s12967-020-02573-9
9. Price, C. C., et al. (2020). Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes. Chest, 158(4), 1397–1408. https://doi.org/10.1016/j.chest.2020.06.006
10. Abolghasemi, H., et al. (2020). Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 59(5), 102875. https://doi.org/10.1016/j.transci.2020.102875 Duan, K., et al. (2020). Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America, 117(17), 9490–9496. https://doi.org/10.1073/pnas.2004168117
11. Salazar, E., et al. (2020). Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. The American journal of pathology, 190(8), 1680–1690. https://doi.org/10.1016/j.ajpath.2020.05.014
12. Allahyari, A., et al. (2021). Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome. International immunopharmacology, 93, 107239. https://doi.org/10.1016/j.intimp.2020.107239
13. S L, G W. Examination Technique and Normal Findings. In: Radiology of Chest Disease. 3rd ed. New York: Thieme; 2007. p. 1–49
14. Jain V, Bhardwaj A. Pneumonia Pathology. NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. Pennsylvania: StatPearls Publishing LLC; 2020
15. Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, et al. COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives. Trends Mol Med [Internet]. 2020;1– Available from: https://doi.org/10.1016/j.molmed.2020.02.008
16. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11
17. Rojas, M., Rodríguez, Y., Monsalve, D. M., Acosta-Ampudia, Y., Camacho, B., Gallo, J. E., Rojas-Villarraga, A., Ramírez-Santana, C., Díaz-Coronado, J. C., Manrique, R., Mantilla, R. D., Shoenfeld, Y., & Anaya, J. M. (2020). Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity reviews, 19(7), 102554. https://doi.org/10.1016/j.autrev.2020.102554
18. Burhan E, Isbaniah F, Susanto AD, Aditama TY, All E. Pneumonia COVID- 19 Diagnonsis & Penatalaksanaan di Indonesia. Perhimpunan Dokter Paru Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2020.
19. COVID-19 Clinical management. Living guidance 25 January 2021. World Health Organization. WHO/2019-nCoV/clinical/2021.1
20. Yang J, Zhou L, Yang Y, et al. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med 2020 Feb 13. doi:10.1016/S2213-2600(20)30071-0
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2024 Aulia Fitriani, Frederica Mardiana Wahyuni, Bambang Satoto, Thomas Handoyo, Antonius Gunawan Santoso, Christina Hari Nawangsih, Nurdopo Baskoro (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
